Booth Mark D 4
4 · Orexigen Therapeutics, Inc. · Filed Feb 19, 2013
Insider Transaction Report
Form 4
Booth Mark D
Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2013-02-15+190,000→ 190,000 totalExercise: $5.69Exp: 2023-02-14→ Common Stock (190,000 underlying)
Footnotes (2)
- [F1]1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/15/2013, so that all of the shares of the stock subject to the option shall be vested on 2/15/2017, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
- [F2]Not applicable.